VEGFA ‐centric angiogenic genetic variants drive hypertension and dyslipidaemia susceptibility in type 2 diabetes mellitus: A multilocus synergistic cohort study
Main finding · VEGFA rs3025020-TT genotype frequencyResult — go to the resultFold comorbidity risk 3.49 95% CI 1.10–11.14Authors' conclusion
These findings underscored VEGFA rs3025020 as a genetic hub coordinating multilocus angiogenic dysregulation, driving HTN and DYS pathogenesis in T2DM. Our results highlight the potential for genotype-guided anti-angiogenic therapies to mitigate metabolic-vascular deterioration in high-risk diabetic populations.
Study context
- Population
- Individuals with T2D, stratified by hypertension (HTN) and dyslipidaemia comorbidity
- Participants
- 440 individuals
- Exposure
- T2DM with HTN and dyslipidaemia (DYS) vs T2DM with HTN vs T2DM only
- T2DM-onlyn = 258reference
- T2DM+HTN (T2MH)n = 130
- T2DM+HTN+DYS (T2MH-DYS)n = 52
- Outcome
- VEGFA rs3025020-TT genotype frequency
Methodological detailsgenetic association, multilocus, Genotyping of VEGFA rs3025020, ANGPT2 rs11137037/rs2442598, TGFB1 rs1800469 and AGTR1 rs5182 by ligase-mediated hybridization and multiplex PCR
- Genetic association
- Multilocus
- Genotyping of VEGFA rs3025020, ANGPT2 rs11137037/rs2442598, TGFB1 rs1800469 and AGTR1 rs5182 by ligase-mediated hybridization and multiplex PCR
Main finding
As reported in the abstract
Fold comorbidity risk
3.49
95% CI 1.10–11.14
P = 0.034
By group
Observational data: associations, not effects.
Further findings
| Outcome | T2MH-DYS | P value |
|---|---|---|
| Fasting glucoseT2MH-DYS vs T2DM-only · elevated in T2MH-DYS; comparator 7.93 mmol/L | 12.60 ± 7.62 mmol/L | P = 0.017 |
| TriglyceridesT2MH-DYS vs T2DM-only · elevated in T2MH-DYS; comparator median 1.68 mmol/L | median 2.48 mmol/L | P < 0.001 |
| CRPT2MH-DYS vs T2DM-only · elevated in T2MH-DYS; comparator 1.79 mg/L | 2.65 mg/L | P = 0.016 |
ANGPT2 rs2442598-CC genotype
- Borderline protective effect, OR
- 0.46 (p = 0.057)
AGTR1 rs5182-TT and HTN grade
- rs5182-TT correlated with milder HTN: Grade I vs Grade III
- 72.2% vs 46.6% (p = 0.008)
Haplotype (AGTR1-ANGPT2-VEGFA) and T2MH-DYS susceptibility
- C-C-T increased susceptibility, fold
- 3.58 (p = 0.0019)
- C-T-C protective, OR
- 0.333 (p = 0.013)
Original publication
VEGFA ‐centric angiogenic genetic variants drive hypertension and dyslipidaemia susceptibility in type 2 diabetes mellitus: A multilocus synergistic cohort study. Diabet Med. Published 12 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →